Tyler Van Horn is the CEO of Science 37, a leader in decentralized clinical trials (DCTs) through its direct-to-patient site solution that improves access, efficiency and inclusivity in clinical research. He brings a proven track record of driving growth, leading transformation and aligning strategic vision with execution across the life sciences industry.
At Science 37, Van Horn is responsible for the company’s overall strategic direction, operational performance and market leadership, including clinical operations, technology, commercial activities and investor relations. He fosters a bold culture that reimagines collaboration, demands accountability and ignites breakthrough innovation to redefine how the world conducts clinical research. Since joining in 2021, Van Horn has reshaped the company’s long-term strategy, implemented disciplined planning processes and led transformative initiatives, including the acquisition of Vault Health’s life sciences platform. His leadership has strengthened pipeline velocity, expanded enterprise partnerships and enhanced operational efficiency, positioning Science 37 for sustainable growth.
Previously, Van Horn served as chief commercial officer and vice president of corporate strategy at Science 37, where he restructured investment priorities and introduced companywide planning cadences. Earlier in his career at IQVIA, he built global product strategy functions and guided large-scale commercial transformations across clinical, commercial and real-world evidence.
Van Horn is recognized for his inclusive leadership style, uniting cross-functional teams around common goals while fostering psychological safety and trust. His work has advanced patient-first approaches to clinical research, broadened trial access for underserved populations and championed health equity across the industry. With expertise spanning biotech, pharma and digital health, Van Horn continues to shape the future of clinical development through innovation, strategic insight and mission-driven leadership.